Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Licenses Stem Cell IP for Drug Screening

NEW YORK (GenomeWeb News) – Cellular Dynamics today said that it has licensed exclusive rights to a patent portfolio covering the optimization of the stem cell differentiation selection process and the use of heart cells in drug testing.

The Madison, Wis.-based firm said that it obtained the license from Loren Field and Indiana University-Purdue University Indianapolis (IUPUI). It covers two concepts for using stem cell-derived cells for drug screening: a cell purification strategy that enables greater than 90 percent purity of any type of cells, and the use of stem cell-derived cardiomyocytes for drug testing.

Financial terms of the deal were not disclosed.

Cellular Dynamics said that it will use the Field technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation to "create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications."

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.